Content Type: Commentary & Opinion

The Implications of Industry-Funded Disease Awareness Campaigns in the Rare Disease Setting

March 16, 2026

Reforming Patient Cost Sharing for Cancer Medications in Medicare Part D

March 16, 2026

Coverage of Magnetic Resonance Imaging for Patients with Cardiac Devices: Improving the Coverage with Evidence Development Program

March 16, 2026

Right to Try Requests and Oncologists’ Gatekeeping Obligations

March 16, 2026

Getting the Right Evidence After Drug Approval

March 16, 2026

The Role of Litigation in Defining Drug Risks

March 16, 2026

Balancing Innovation, Access, and Profits—Market Exclusivity for Biologics

March 16, 2026

State Restrictions on Mifepristone Access—The Case for Federal Preemption

March 16, 2026

Fulfilling the Mandate of the US Food and Drug Administration’s Accelerated Approval Pathway: The Need for Reforms

March 16, 2026

Cell and Gene Therapy Trials: Are We Facing an ‘Evidence Crisis’?

March 16, 2026

Designing Development Programs for Non-Traditional Antibacterial Agents

March 16, 2026

Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease—Estimating the True Value

March 16, 2026